首页|期刊导航|Oncology Research|UCK2 Drives Lung Adenocarcinoma Progression and Immune Dysregulation via the RHEB/mTOR Signaling Axis

UCK2 Drives Lung Adenocarcinoma Progression and Immune Dysregulation via the RHEB/mTOR Signaling AxisOA

中文摘要

Objectives:Uridine-cytidine kinase 2(UCK2)plays a crucial role in the pyrimidine salvage pathway,but its function in lung adenocarcinoma(LUAD)is still largely unclear.The study aimed to investigate the expression,prognostic value,biological functions,and molecular mechanisms of UCK2 in LUAD.Methods:Bioinformatic analyses were performed using The Cancer Genome Atlas(TCGA),Gene Set Cancer Analysis(GSCA),Gene Expression Omnibus(GEO),and Genotype Tissue Expression(GTEx)datasets.In vitro assays evaluated the effect of UCK2 overexpression on LUAD cells.Co-immunoprecipitation and pathway analyses were utilized to explore the underlying mechanism.Immune landscape and drug sensitivity analyses were also carried out.Results:UCK2 was markedly upregulated in LUAD tissues,correlating with advanced tumor stage and poor overall survival,and served as an independent prognostic factor.Functionally,overexpression of UCK2 increased the proliferation and migration of LUAD cells.Mechanistically,UCK2 interacted with the small GTPase Ras homolog enriched in brain(RHEB)and regulated the mechanistic target of rapamycin(mTOR)signaling pathway.UCK2 expression was also associated with specific immune profiles and drug sensitivity in LUAD.Conclusion:UCK2 acts as a prognostic indicator and oncogene in LUAD,at least partly via the RHEB/mTOR axis.Targeting UCK2 may represent a promising therapeutic approach for LUAD.

XiaolinWei;Jing Guo;Chuntao Tao;Yong Bao;Li Yang;Hong Chen

Department of Respiratory and Critical Care Medicine,The First Affiliated Hospital,Chongqing Medical University,Chongqing,China Department of Respiratory Medicine,Sichuan Taikang Hospital,Chengdu,ChinaDepartment of Respiratory and Critical Care Medicine,The First Affiliated Hospital,Chongqing Medical University,Chongqing,ChinaDepartment of Biochemistry and Molecular Biology,College of Basic Medical Sciences,Chongqing Medical University,Chongqing,ChinaDepartment of Respiratory Medicine,Sichuan Taikang Hospital,Chengdu,ChinaDepartment of Respiratory and Critical Care Medicine,The First Affiliated Hospital,Chongqing Medical University,Chongqing,ChinaDepartment of Respiratory and Critical Care Medicine,The First Affiliated Hospital,Chongqing Medical University,Chongqing,China

医药卫生

Uridine-cytidine kinase 2(UCK2)lung adenocarcinoma(LUAD)prognostic biomarkerRHEB/mTOR signalingdrug sensitivity

《Oncology Research》 2026 (6)

P.630-659,30

supported by grants from the National Natural Science Foundation of China(Grant No.82470016,to Hong ChenGrant No.82203181,to Li Yang)the Hospital-Level Scientific Research Project of Sichuan Taikang Hospital(Grant No.Z004000173,to Xiaolin Wei).

10.32604/or.2026.078651

评论